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Results From the A to Z Trial
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Objectives This study sought to determine whether the novel biomarker monocyte chemoattractant protein (MCP)-1 adds
prognostic value to standard risk assessment tools and biomarkers after acute coronary syndromes (ACS).
Background Monocyte chemoattractant protein-1 is a chemokine recruiting signal for monocytes that may function as both a
mediator and biomarker of ACS.
Methods Monocyte chemoattractant protein-1 was measured at baseline (n  4,244), 4 months (n  3,603), and 12
months (n  2,950), and correlated with clinical events in the Z phase of the A to Z (Aggrastat to Zocor) trial,
which compared early intensive versus delayed and less intensive statin therapy after ACS.
Results Rates of death and the composite end points of death or myocardial infarction (MI); death, MI, or heart failure;
and cardiovascular death, MI, readmission for ACS, or stroke increased across baseline quartiles of MCP-1 and
among patients with MCP-1 greater than versus less than or equal to the pre-specified threshold of 238 pg/ml
(p  0.01 for each). After adjustment for standard risk predictors and levels of C-reactive protein and B-type na-
triuretic peptide, MCP-1 238 pg/ml remained independently associated with mortality (hazard ratio 2.16; 95%
confidence interval 1.54 to 3.02) and with each composite end point, and increased the C-statistic of the fully
adjusted mortality model from 0.76 to 0.78 (p  0.0001). A value of MCP-1 238 pg/ml at the 4-month
follow-up visit was also independently associated with mortality after 4 months (hazard ratio 1.76; 95% confi-
dence interval 1.12 to 2.76). Elevated MCP-1 levels did not identify patients who derived incremental benefit
from intensive statin therapy.
Conclusions Monocyte chemoattractant protein-1 provides independent prognostic value in the acute and chronic phases
after ACS and merits further evaluation as a prognostic marker and potential therapeutic target. (J Am Coll
Cardiol 2007;50:2117–24) © 2007 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2007.06.057B
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been identified. Monocyte che-
moattractant protein (MCP)-1 is
a member of the C-C chemokine
family that is produced by mono-
cytes/macrophages, smooth mus-
cle cells, and endothelial cells
within atherosclerotic plaques (1).
It is recognized by CCR-2 re-
ceptors on monocytes and serves
as a chemotactic agent to recruit
monocytes into the vascular wall
(2). In animal models, atheroscle-
rosis is promoted when MCP-1
expression is increased (3), and is
inhibited when the gene for ei-
her MCP-1 (4) or CCR-2 (5) is deleted. Monocyte
hemoattractant protein-1 stimulates tissue factor (6) and
uperoxide (7) production by monocytes, which may con-
ribute to the transition from stable atherosclerosis to the acute
oronary syndrome (ACS) phenotype.
The role of MCP-1 in human atherosclerosis is sup-
orted by reports of higher MCP-1 levels and increased
ates of myocardial infarction (MI) associated with certain
olymorphisms in the MCP-1 gene (8). Moreover, in
opulation studies, plasma levels of MCP-1 are positively
orrelated with most cardiovascular risk factors, with mea-
ures of coronary atherosclerosis burden, and with incident
oronary and peripheral artery disease (9–11). In prelimi-
ary studies performed in patients with ACS, higher levels
f MCP-1 have been associated with an increased risk for
eath and recurrent ischemic events, independent of stan-
ard risk predictors (12,13). These studies, however, have
ot evaluated the prognostic value of MCP-1 after account-
ng for more established biomarkers, including C-reactive
rotein (CRP) (14) and B-type natriuretic peptide (BNP)
15,16). Moreover, studies to date have focused on mea-
urements of MCP-1 during the initial ACS hospitaliza-
ion, and few data are available in the chronic phase after
CS.
Both MCP-1 and CCR-2 have emerged as attractive
argets for existing and novel therapies, based on the
nimal studies described above, as well as on human
tudies showing that effective preventive therapies such as
tatins (17–19) and thiazolinediones (20) reduce cellular
xpression and circulating levels of MCP-1. We evalu-
ted measurement of MCP-1 in a large population of
atients stabilized after ACS and enrolled in the A to Z
Aggrastat to Zocor) trial, to determine whether: 1)
easurement of MCP-1 in the hospital setting and/or
uring outpatient follow-up adds to the prognostic value
f standard measurements such as creatinine clearance
nd low-density lipoprotein cholesterol (LDL-C), as well
s emerging biomarkers such as CRP and BNP; 2)
lasma levels of MCP-1 were modified by intensive statin
Abbreviations
and Acronyms
ACS  acute coronary
syndrome
BNP  B-type natriuretic
peptide
CRP  C-reactive protein
LDL-C  low-density
lipoprotein cholesterol
MCP  monocyte
chemoattractant protein
MI  myocardial infarction
ULN  upper limit of
normalherapy; and 3) elevated MCP-1 levels could identify catients who derived incremental benefit from intensive
tatin therapy.
ethods
tudy population. The design and primary results of the A
o Z trial have been previously reported (21,22). Phase A
as an open-label noninferiority trial comparing enoxaparin
ith unfractionated heparin among patients with non–ST-
egment elevation ACS also receiving tirofiban and aspirin
23). Phase Z was a randomized, double-blind trial per-
ormed in 4,497 patients ages 21 to 80 years with non–ST-
egment elevation ACS or ST-segment elevation MI, in
hich an early intensive statin strategy (simvastatin 40
g/day for 1 month, followed by 80 mg/day through the
nd of the study) was compared with a delayed and less
ntensive strategy (placebo for 4 months followed by sim-
astatin 20 mg/day through the end of the study). Patients
ere excluded from participation in the A to Z trial if they
ere taking a statin at the time of enrollment, if they had a
erum creatinine level 2 mg/dl, or if revascularization was
lanned. Follow-up was for at least 6 months and up to 2
ears. The current study population included all patients
nrolled in Phase Z with a blood sample available for
easurement of MCP-1 at either baseline or 4 months.
easurement of MCP-1 and other biomarkers. Plasma
as collected in tubes containing ethylenediamine tetracetic
cid at the time of enrollment into Phase Z (median 3.5
ays after symptom onset), and at the 4- and 12-month
isits, and shipped refrigerated overnight to a central
torage facility, where aliquots were frozen at 80°C.
liquots were shipped on dry ice to the TIMI (Throm-
olysis In Myocardial Ischemia) Core Laboratory at the
righam and Women’s Hospital Clinical Laboratories,
here they were analyzed in batch. Monocyte chemoattrac-
ant protein-1 was measured on the automated enzyme
mmunoassay analyzer Triturus (Grifols USA, Miami, Flor-
da) using the human MCP-1 enzyme-linked immunosor-
ent assay (Bender MedSystems, Burlingame, California).
he limit of detection was 2.31 pg/ml. The coefficient of
nterassay variation was 8.7%.
High-sensitivity testing for CRP was performed as pre-
iously described using the CRP-Latex (II) immunoturbi-
imetric assay (Denka Seiken, Tokyo, Japan) on a Hitachi
11 immunoanalyzer (Roche Diagnostics, Indianapolis,
ndiana) (14). The pre-specified level for defining CRP
levation at baseline (during the acute phase of ACS) was
5 mg/l (24), and during the chronic phase was 3 mg/l
25). Brain natriuretic peptide was measured using the
DVIA Centaur BNP assay (Bayer Healthcare LLC,
arrytown, New York) as previously described (16).
rain natriuretic peptide elevation was pre-specified as
80 pg/ml based on previous work with this analyte (15).
ll biomarkers were measured by personnel blinded tolinical outcomes and treatment allocation.
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November 27, 2007:2117–24 Serial Measurement of MCP-1 After ACStudy end points. The primary outcome for this substudy
as all-cause mortality. As secondary end points, we also
valuated MI; and the composites of death and MI; and
eath, MI, and new or worsening heart failure; as well as the
hase Z trial primary end point of cardiovascular death, MI,
eadmission for ACS, and stroke. Cardiovascular death
ncluded sudden death and death caused by pump failure,
I, stroke, or after a cardiovascular procedure. An MI was
efined as ischemic symptoms or electrocardiographic
hanges plus elevation in cardiac biomarkers 2 upper
imit of normal (ULN). Procedural MI required either
athologic Q waves or biomarker elevation 3 ULN
percutaneous coronary intervention) or 5 ULN (coro-
ary artery bypass graft). An ACS was defined as ischemic
ymptoms plus either 0.5 mm ST-segment deviation, 2
m T-wave change, or biomarker elevation greater than or
qual to the ULN but below the MI threshold. Stroke was
efined as a sudden focal neurological deficit not reversible
ithin 24 h. New or worsening heart failure required
nitiation or titration of heart failure medications. All end
oints except for heart failure were adjudicated by a Clinical
vents Committee.
tatistical methods. Patients were divided into quartiles
ased on the distribution of MCP-1 at baseline and at 4
onths. Based on our previous substudy of the OPUS-
Orbofiban in Patients with Unstable coronary Syndromes)-
IMI 16 trial showing that MCP-1 levels238 pg/ml were
ndependently associated with death and MI after ACS
12), we also pre-specified a threshold of 238 pg/ml as a
ichotomous threshold for the present analyses.
Baseline characteristics were compared across MCP-1
uartiles using the chi-square trend test for categorical
ariables and the “nptrend” test for continuous variables (an
xtension of the Wilcoxon rank-sum test). The Wilcoxon
ank-sum test was used to compare MCP-1 levels between
reatment groups. Event rates were estimated using the
aplan-Meier method and compared between groups using
he log-rank test. Stratified analyses were performed using
he pre-specified levels of CRP and BNP described above.
ox proportional hazards models were used to adjust for
aseline variables known to be associated with adverse
utcomes in ACS, including age, gender, weight, prior MI,
istory of diabetes, current smoking, index diagnosis, cre-
tinine clearance, use of ACE inhibitors, randomized treat-
ent assignment, and levels of LDL-C, CRP, and BNP (all
s continuous variables). The C-statistic (analogous to the
rea under the receiver-operator characteristic curve) was
alculated, and the likelihood ratio test was used to compare
he discrimination of the models before and after the
ddition of MCP-1.
Analyses of the association of the 4-month MCP-1
evels and the changes in MCP-1 from baseline to 4
onths with subsequent outcomes were performed using
landmark analysis beginning at 4 months. These anal-
ses do not preserve randomization, which was performed
t baseline; therefore comparisons between treatment 1roups based on 4-month MCP-1 values should be
onsidered exploratory only. Cox proportional hazards
odels were performed with adjustment for age, gender,
istory of diabetes, current smoking, index diagnosis,
reatment assignment, and levels of LDL-C, CRP, and
NP measured at 4 months.
All analyses were performed by the TIMI Study Group
sing STATA 9.2 (STATA Corporation, College Station,
exas).
esults
o differences in baseline characteristics were detected
etween the overall Phase Z study population (n  4,497)
nd the subgroups with MCP-1 measured at baseline (n 
,244), at 4 months (n  3,603), or at 12 months (n 
,950) (data not shown). Clinical characteristics according
o levels of MCP-1 at baseline are shown in Table 1. Higher
CP-1 levels were associated with older age, female gen-
er, diabetes, hypertension, prior MI or heart failure, prior
spirin use, lower creatinine clearance, higher triglycerides,
nd lower HDL cholesterol (p  0.01 for each). Baseline
CP-1 levels were not associated with baseline CRP or
NP levels, but were associated with 1-month CRP levels
n the placebo group (Table 1). Although MCP-1 levels
ere lower among smokers in univariable analyses, this
ifference disappeared after adjustment for age (p  0.24).
nfluence of statin therapy on MCP-1 levels. Monocyte
hemoattractant protein-1 levels were similar at baseline in
he 2 treatment groups (p  0.46). Over the first 4 months,
he median increase in MCP-1 was greater in the placebo
rm than in the simvastatin 40 mg/80 mg arm (24 vs. 13
g/ml; p  0.002), resulting in modestly lower MCP-1
evels in the simvastatin 40 mg/80 mg arm at 4 months (p
0.005) (Fig. 1). At 12 months, reflecting the comparison
f simvastatin 80 mg versus simvastatin 20 mg, no differ-
nces in MCP-1 levels were seen (p  0.22) (Fig. 1).
ssociation between baseline MCP-1 levels and out-
omes. Rates of each of the end points, including death;
I; the composite end point of death or MI; the composite
nd point of death, MI, or heart failure; and the primary
hase Z composite increased across baseline quartiles of
CP-1 (p  0.01 for each) (Table 2). Please note that risk
n the 4th quartile did not exceed that in the 3rd quartile.
atients above the pre-specified MCP-1 cutoff point of 238
g/ml were also at increased risk for mortality (p  0.0001)
Fig. 2), as well as each of the secondary end points (p 
.01 for each) (Table 2). In stratified analyses, patients with
CP-1 levels 238 pg/ml were at increased risk for
ortality whether CRP was 15 or 15 mg/l or whether
NP was 80 or 80 pg/ml (Fig. 3). In multivariable
nalyses adjusting for baseline variables, index diagnosis,
reatinine clearance, LDL-C, CRP, and BNP, a baseline
CP-1 level 238 pg/ml remained associated with mor-
ality (adjusted hazard ratio 2.16; 95% confidence interval
.54 to 3.02), and with each of the other end points
(
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Serial Measurement of MCP-1 After ACS November 27, 2007:2117–24Table 2). The addition of MCP-1 increased the C-statistic
f the fully adjusted mortality model from 0.76 to 0.78 (p
.0001).
ollow-up measurements of MCP-1 and subsequent
utcomes. Increasing quartiles of MCP-1 measured at 4
onths were also associated with the end point of death; the
omposite end point of death or MI; the composite end
ssociation Between Enrollment Clinical Variables and Baseline Le
Table 1 Association Between Enrollment Clinical Variables and
Variable
Quartile 1
(<190 pg/ml)
n  1,070
Qu
(190–2
n 
Age, yrs 58 (50, 67) 60 (
Weight, kg 79 (69, 89) 80 (
Female gender, % 20
White race, % 86
Current smoker, % 46
Diabetes, % 19
Hypertension, % 47
Family history of premature coronary
artery disease, %
20
Prior MI, % 14
Prior CHF, % 4
Prior chronic aspirin use, % 28
ACE inhibitor use, % 54
Index ST-segment elevation MI, % 42
Creatinine clearance, ml/min 79 (64, 97) 77 (
Total cholesterol, mg/dl* 183 (162, 203) 184 (
LDL cholesterol, mg/dl* 112 (93, 130) 111 (
HDL cholesterol, mg/dl* 39 (34, 46) 39 (
Triglycerides, mg/dl* 140 (109, 186) 145 (
CRP, mg/l 22 (8, 48) 19 (
CRP at 1 month, mg/l† 2.1 (1.1, 4.7) 2.3 (
BNP, pg/ml 11 (0, 42) 11 (
ategoric data are reported as percentages and continuous data as median (25th, 75th percentil
-month values from the placebo group only. †Placebo group only.
ACE  angiotensin-converting enzyme; BNP  brain natriuretic peptide; CHF  congestive hea
yocardial infarction.
Figure 1 Influence of Early and Intensive Statin
Therapy on Median Plasma Levels of MCP-1
Although levels of monocyte chemoattractant protein (MCP)-1 were significantly
lower in the simvastatin 40 mg/80 mg arm at 4 months, the difference
between the groups was quantitatively modest.point of death, MI, or heart failure; and the primary Phase
composite end point (p  0.01 for each) (Table 3). No
ssociation was observed between 4-month MCP-1 quar-
iles and subsequent MI. When the threshold of 238 pg/ml
or MCP-1 was used, a significant association was observed
etween MCP-1 and mortality (Fig. 4) and each of the
omposite end points (Table 3). Although modestly atten-
ated, the association between 4-month levels of MCP-1
nd subsequent outcomes remained significant after multi-
ariable adjustment that included age, gender, history of
iabetes, current smoking, index diagnosis, treatment as-
ignment, and levels of LDL-C, CRP, and BNP at 4
onths (Table 3). The addition of 4-month MCP-1 levels
o the 4-month mortality models increased the C-statistic
rom 0.72 to 0.73 (p  0.01).
The 3,467 subjects who had MCP-1 measurements
erformed at both baseline and 4 months were categorized
nto 4 groups based on whether MCP-1 was238 pg/ml at
oth baseline and 4-month follow-up (n  1,580 [45.6%]),
238 pg/ml at baseline but 238 pg/ml at follow-up (n 
23 [9.3%]), 238 pg/ml at baseline but 238 pg/ml at
ollow-up (n  601 [17.3%]), or 238 pg/ml at both time
oints (n  963 [27.8%]). Mortality after 4 months was
igher among patients with MCP-1 levels 238 pg/ml at
oth the baseline evaluation and the 4-month visit, com-
of MCP-1
eline Levels of MCP-1
2
/ml)
2
Quartile 3
(256–350 pg/ml)
n  1,074
Quartile 4
(>350 pg/ml)
n  1,048 p Trend
) 62 (53, 70) 64 (55, 71) 0.001
) 80 (70, 90) 79 (69, 90) 0.63
27 31 0.001
85 85 0.72
39 35 0.001
23 23 0.008
51 53 0.001
22 21 0.51
17 20 0.001
4 7 0.001
36 38 0.001
57 58 0.10
38 39 0.11
) 76 (60, 93) 71 (55, 89) 0.001
04) 187 (168, 208) 186 (163, 206) 0.008
0) 113 (97, 132) 111 (93, 131) 0.43
) 39 (33, 45) 38 (32, 45) 0.009
94) 153 (118, 206) 158 (123, 209) 0.001
20 (8, 43) 19 (8, 47) 0.29
1) 3.2 (1.4, 6.5) 2.6 (1.3, 5.7) 0.001
12 (0, 42) 13 (0, 50) 0.24
analysis of the association between lipids and monocyte chemoattractant protein (MCP-1) used
e; CRP  C-reactive protein; HDL  high-density lipoprotein; LDL  low-density lipoprotein; MI vels
Bas
artile
55 pg
1,05
52, 69
70, 90
19
86
41
19
49
21
17
5
30
56
40
62, 94
163, 2
94, 13
34, 46
114, 1
8, 43)
1.2, 5.
0, 45)
e). *Theared with those in the other 3 groups (p  0.004) (Fig. 5).
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November 27, 2007:2117–24 Serial Measurement of MCP-1 After ACSffect of intensive statin therapy in subgroups defined by
CP-1 levels. Randomization to the early intensive statin
rm was associated with similar effects in patients with
aseline (Table 4) or 4-month (Table 5) MCP-1 levels
238 versus 238 pg/ml. Findings were unchanged when
atients were divided at the median MCP-1 level (data not
hown).
ombined measurement of MCP-1, CRP, and BNP. A
trong, stepwise association was observed between the
umber of biomarkers that were above the pre-specified
hresholds and subsequent mortality, both for baseline
easurements as well as for 4-month measurements. After
ultivariable adjustment, a 7-fold gradient was observed
etween those subjects with 0 versus all 3 markers elevated
t either time point (Fig. 6).
iscussion
n a large and well-characterized population of patients
tabilized early after ACS, we found that higher MCP-1
evels were associated with an increased risk for long-term
ssociation Between MCP-1 Levels at Baseline and Events Throug
Table 2 Association Between MCP-1 Levels at Baseline and Ev
End Point
Quartile 1
(<190 pg/ml)
n  1,070
Quartile 2
(190–255 pg/ml)
n  1,052
Quartile
(256–350 pg
n  1,07
Death, % 2.6 5.0 8.4
Adjusted HR (95% CI) 1 (referent) 1.81 (1.07–3.08) 3.13 (1.92–5
MI, % 5.3 6.5 8.6
Adjusted HR (95% CI) 1 1.25 (0.85–1.86) 1.63 (1.13–2
Death or MI, % 7.5 11.0 14.3
Adjusted HR (95% CI) 1 1.41 (1.02–1.95) 1.82 (1.34–2
Death/MI/CHF, % 10.1 13.8 17.1
Adjusted HR (95% CI) 1 1.35 (1.01–1.79) 1.64 (1.25–2
A to Z primary composite, % 11.7 14.8 16.6
Adjusted HR (95% CI) 1 1.19 (0.91–1.54) 1.31 (1.02–1
ll models adjusted for age, gender, weight, prior MI, use of ACE inhibitors, history of diabetes, curre
CI  confidence interval; HR  heart rhythm; other abbreviations as in Table 1.
2
4
6
8
0 120 240 360 480 600 720
MCP-1 < 238 pg/mL
MCP-1 > 238 pg/mL
M
o
rt
al
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y 
(%
)
Days Following Randomization
p<0.0001
Figure 2 Baseline MCP-1 Levels and Mortality After ACS
Nelson-Aalen cumulative hazard estimates comparing patients with baseline
monocyte chemoattractant protein (MCP)-1 levels 238 versus 238 pg/ml.
ACS  acute coronary syndrome.eath and major adverse cardiac outcomes, independent of
tandard measurements such as creatinine clearance and
DL-C, as well as established biomarkers such as CRP and
NP. In addition, MCP-1 levels measured 4 months after
CS also provided independent prognostic value. Mono-
yte chemoattractant protein-1 appeared to be more
trongly associated with mortality than with composite
utcomes that included nonfatal end points. At both base-
of Study
Through End of Study
Quartile 4
(>350 pg/ml)
n  1,048 p Trend
MCP-1
(<238 pg/ml)
n  1,860
MCP-1
(>238 pg/ml)
n  2,384 p Value
6.7 0.0001 3.4 7.4 0.0001
2.26 (1.37–3.73) 1 (referent) 2.16 (1.54–3.02)
8.0 0.009 5.7 8.2 0.003
1.25 (0.85–1.86) 1 1.33 (1.02–1.74)
13.5 0.0001 8.7 13.8 0.0001
1.51 (1.10–2.07) 1 1.46 (1.18–1.82)
15.8 0.0001 11.3 16.4 0.0001
1.34 (1.01–1.77) 1 1.36 (1.12–1.65)
18.1 0.0001 12.8 17.2 0.0001
1.26 (0.98–1.63) 1 1.20 (1.00–1.44)
king, index diagnosis, treatment assignment, creatinine clearance, LDL cholesterol, CRP, and BNP.
A
0
2
4
6
8
10
CRP high  CRP low
MCP-1 high
MCP-1 low
M
o
rt
al
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y
(%
) p<0.0001
p<0.001
n=1029
n=676
n=1266
n=924
B
0
5
10
15
20
BNP high  BNP low
MCP-1 high
MCP-1 low
M
o
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y
(%
)
n=253
n=353
n=1605
n=2030
p=0.08
p<0.0001
Figure 3 Association Between Baseline
Levels of MCP-1 and Mortality
Levels are stratified by C-reactive protein (CRP) (A) and brain natriuretic peptide
(BNP) (B). High monocyte chemoattractant protein (MCP)-1 levels are defined as
238 pg/ml, high CPR as 15 mg/l, and high BNP as 80 pg/ml.h End
ents
3
/ml)
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Serial Measurement of MCP-1 After ACS November 27, 2007:2117–24ine and 4 months, the addition of MCP-1 to the fully
djusted multivariable models modestly but significantly
mproved discrimination for mortality, as assessed by the
-statistic and the likelihood ratio tests, which have been
dvocated as rigorous statistical tools for the evaluation of
ew biomarkers (26). Finally, when included in a simple
ultiple-biomarker panel with CRP and BNP, a strong,
raded, and independent association was shown between
he number of elevated markers and subsequent mortality.
hese findings suggest that MCP-1 may have value as
biomarker for risk stratification in both the initial and
he chronic phases after an ACS event, and support addi-
ional investigation of MCP-1 (and CCR-2) as therapeutic
argets.
We also prospectively confirmed that an MCP-1 thresh-
ld of 238 pg/ml, derived from a previous large study of
atients with ACS (12), identifies patients at increased risk
or adverse events in both the acute and the chronic setting
fter ACS. Patients with levels persistently above this
ssociation Between MCP-1 Levels at 4 Months and Events From
Table 3 Association Between MCP-1 Levels at 4 Months and E
End Point
Quartile 1
(<210 pg/ml)
n  907
Quartile 2
(210–273 pg/ml)
n  895
Quartile
(274–364 p
n  89
Death, % 2.0 3.3 3.8
Adjusted HR (95% CI) 1 (referent) 2.06 (1.08–3.96) 2.01 (1.06
MI, % 2.4 3.0 3.9
Adjusted HR (95% CI) 1 1.40 (0.75–2.62) 1.55 (0.84
Death or MI, % 4.0 5.7 7.1
Adjusted HR (95% CI) 1 1.61 (1.01–2.57) 1.74 (1.11
Death/MI/CHF, % 4.5 6.9 8.3
Adjusted HR (95% CI) 1 1.71 (1.19–2.62) 1.76 (1.16
A to Z primary composite, % 5.7 7.2 8.4
Adjusted HR (95% CI) 1 1.35 (0.92–2.00) 1.30 (0.89
ll models adjusted for age, gender, history of diabetes, current smoking, index diagnosis, treatm
Abbreviations as in Tables 1 and 2.
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Figure 4 MCP-1 Levels at 4 Months
After ACS and Subsequent Mortality
Nelson-Aalen cumulative hazard estimates showing the association between
monocyte chemoattractant protein (MCP)-1 levels 238 versus 238 pg/ml at
4 months and mortality from 4 months through the end of the study period.
Events before 4 months were censored. ACS  acute coronary syndrome.hreshold seemed to be at particularly high risk for death
ompared with those with persistently lower levels, or levels
hat were only transiently above this threshold.
Because MCP-1 plays a direct pathogenic role in athero-
clerosis development and progression and also stimulates
issue factor and oxidant production, the predictive value of
CP-1 may reflect increased atherosclerotic burden, en-
anced plaque vulnerability, or both. Of particular impor-
ance is the finding that MCP-1 provides prognostic infor-
ation that is not redundant with that provided by CRP. In
ontrast to CRP, which increases markedly in response to
he ACS event, MCP-1 levels changed little between
aseline and 4 months, suggesting that plasma MCP-1
evels may reflect chronic rather than acute pathophysiologic
rocesses. Although relatively little is known about the
inetics of MCP-1 release into the plasma, we and others
ave reported that MCP-1 levels are only slightly higher
n patients with ACS than in normal control subjects
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Figure 5 Serial Changes in MCP-1 and Subsequent Mortality
Nelson-Aalen cumulative hazard estimates in subgroups defined by monocyte
chemoattractant protein (MCP)-1 levels at baseline and at 4 months. High
MCP-1 levels are defined as 238 pg/ml and low as 238 pg/ml. Each curve
represents a subgroup defined by baseline/4 month MCP-1 levels. Events
before 4 months were censored. Patients with MCP-1 levels 238 pg/ml at
both baseline and 4 months had significantly higher mortality rates compared
with the other groups.
nths Through End of Study
s From 4 Months Through End of Study
)
Quartile 4
(>364 pg/ml)
n  902 p Trend
MCP-1
(<238 pg/ml)
n  1,333
MCP-1
(>238 pg/ml)
n  2,270 p Value
4.5 0.009 2.3 4.0 0.009
2.23 (1.19–4.18) 1 1.76 (1.12–2.76)
3.5 0.11 2.8 3.4 0.48
1.52 (0.82–2.81) 1 1.09 (0.71–1.68)
7.2 0.005 4.8 6.7 0.01
1.74 (1.11–2.74) 1 1.40 (1.02–1.94)
8.1 0.003 5.4 7.9 0.004
1.65 (1.08–2.51) 1 1.40 (1.04–1.88)
9.3 0.007 6.3 8.4 0.04
1.51 (1.04–2.20) 1 1.23 (0.93–1.61)
ignment, LDL cholesterol, CRP, and BNP.4 Mo
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November 27, 2007:2117–24 Serial Measurement of MCP-1 After ACS12,13), a finding that indicates that MCP-1 will not be
seful as a diagnostic marker in ACS but rather may be
stable indicator of long-term cardiovascular risk. This
ypothesis is supported by data from population studies,
n which plasma levels of MCP-1 reflect the burden of
oronary artery disease risk factors and the presence of
ubclinical atherosclerosis and correlate poorly with
cute-phase reactants such as CRP (9,11). Even when
easured at 4 months, a time when CRP levels would be
xpected to reflect the chronic state rather than the acute
nfluences of the ACS event, MCP-1 levels clearly
rovided prognostic information that was independent of
hat provided by CRP.
Previous studies in animals and humans have reported
hat statins significantly reduce cellular expression of
CP-1 and the CCR-2 receptor as well as circulating levels
f MCP-1 in plasma (17–19). Here, in a study more than
0-fold larger than these previous studies, although we did
nd that early and intensive treatment with simvastatin after
CS resulted in significantly lower MCP-1 levels versus
lacebo, this effect was quantitatively very modest. At 12
onths, reflecting a comparison of 20- and 80-mg doses of
imvastatin, MCP-1 levels were similar between the 2 arms.
oreover, we found no evidence showing that higher
CP-1 levels identified patients more likely to benefit from
ggressive statin therapy. We have also recently reported the
bsence of an interaction between CRP levels, treatment
ssignment, and clinical outcomes in the A to Z study (14).
hese findings suggest that MCP-1 measurement will not
e useful as a tool for monitoring statin therapy or for
dentifying patients for more aggressive statin treatment.
owever, given the clear pathogenic role for MCP-1 in
therosclerosis and its complications, and the association of
lasma levels of MCP-1 with coronary risk factors, athero-
clerosis burden, and clinical events, MCP-1 should be
azard Ratios Comparing Early Intensive Versusel yed Con ervative Simv statin Stratified byseline MCP-1 Le ls
Table 4
Hazard Ratios Comparing Early Intensive Versus
Delayed Conservative Simvastatin Stratified by
Baseline MCP-1 Levels
End Point MCP-1 <238 pg/ml MCP-1 >238 pg/ml
Death 0.67 (0.41–1.12) 0.83 (0.61–1.12)
Death or MI 0.81 (0.59–1.11) 0.90 (0.72–1.12)
Death/MI/CHF 0.74 (0.56–0.99) 0.89 (0.73–1.10)
A to Z primary 0.84 (0.64–1.08) 0.87 (0.71–1.06)
ll interaction p values 0.3.
Abbreviations as in Table 1.
azard Ratios Comparing 80 mg Versus 20 mgimvastatin Stratified by 4-Month MCP-1 Levels
Table 5 Hazard Ratios Comparing 80 mg Versus 20 mgSimvastatin Stratified by 4-Month MCP-1 Levels
End Point MCP-1 <238 pg/ml MCP-1 >238 pg/ml
Death 0.48 (0.22–1.04) 0.77 (0.50–1.18)
Death or MI 0.54 (0.32–0.93) 0.89 (0.64–1.24)
Death/MI/CHF 0.62 (0.38–1.00) 0.87 (0.65–1.18)
A to Z primary 0.79 (0.51–1.22) 0.76 (0.56–1.02)i
ll interaction p values 0.1.
Abbreviations as in Table 1.urther studied as a biomarker “target” for novel atheroscle-
osis therapies.
Monocyte chemoattractant protein-1 has also shown
ome promise as a biomarker for disease monitoring in other
nflammatory diseases, such as juvenile rheumatoid arthritis,
here plasma levels decrease concordant with clinical signs
f improvement and persistent reductions seem to predict
onger remission (27). Future studies testing more specific
nti-inflammatory therapies will be needed to determine
hether MCP-1 has a sufficient dynamic range to be useful as
measurable target for atherosclerosis therapies. Specific cyto-
ine antagonists, including monoclonal antibodies against
CP-1 and CCR-2, are currently under investigation in
heumatoid arthritis (28). If these therapies are proven safe,
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Figure 6 Incorporation of MCP-1
Into a Multiple Biomarker Panel
Unadjusted association between the number of elevated biomarkers (monocyte
chemoattractant protein [MCP]-1, brain natriuretic peptide [BNP], and C-reactive
protein [CRP]) at baseline (A) and at 4 months (B) and subsequent mortality.
An MCP-1 elevation was defined as 238 pg/ml, and BNP elevation as 80
pg/ml; CRP elevation at baseline was defined as 15 mg/l and at 4 months
as 3 mg/l. Multivariable adjustment is shown at the bottom of each panel
using variables described in the text. HR  hazard ratio.nvestigation in atherosclerosis may be warranted as well.
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lasma levels of MCP-1 provide prognostic value in both
he acute and the chronic period after ACS that is comple-
entary to that of standard clinical variables and emerging
iomarkers such as CRP and BNP. The influence of statins
n MCP-1 is modest, and MCP-1 is not useful for
dentifying patients who benefit from aggressive statin
egimens after ACS. Future studies are needed to evaluate
hether MCP-1 should be included in multiple-biomarker
anels for risk stratification and whether this biomarker can be
sed as a measurable target for antiatherosclerosis therapies.
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